Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash & Current Investments: 2014-2024

Historic Cash & Current Investments for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to $212.6 million.

  • Cartesian Therapeutics' Cash & Current Investments fell 34.59% to $143.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $696.8 million, marking a year-over-year increase of 43.14%. This contributed to the annual value of $212.6 million for FY2024, which is 176.44% up from last year.
  • According to the latest figures from FY2024, Cartesian Therapeutics' Cash & Current Investments is $212.6 million, which was up 176.44% from $76.9 million recorded in FY2023.
  • Cartesian Therapeutics' 5-year Cash & Current Investments high stood at $212.6 million for FY2024, and its period low was $76.9 million during FY2023.
  • Over the past 3 years, Cartesian Therapeutics' median Cash & Current Investments value was $134.6 million (recorded in 2022), while the average stood at $141.4 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Cash & Current Investments plummeted by 42.86% in 2023 and then spiked by 176.44% in 2024.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Cash & Current Investments stood at $138.7 million in 2020, then decreased by 7.66% to $128.1 million in 2021, then increased by 5.11% to $134.6 million in 2022, then slumped by 42.86% to $76.9 million in 2023, then soared by 176.44% to $212.6 million in 2024.